Listed

XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2018

Filed with the SEC on Mar 11, 2019 and accepted by EDGAR at Mar 11, 2019, 20:22 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2018-01-01 to 2018-12-31−$793.0kifrs-full:ProfitLossFromOperatingActivities
Net income12 months2018-01-01 to 2018-12-31$3.0mifrs-full:ProfitLoss
Operating cash flow12 months2018-01-01 to 2018-12-31−$816.0kifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2018-12-31$3.3mifrs-full:CashAndCashEquivalents
Current assetsAt period end2018-12-31$8.2mifrs-full:CurrentAssets
Total assetsAt period end2018-12-31$8.6mifrs-full:Assets
Shareholders' equityAt period end2018-12-31$8.3mifrs-full:Equity

Source: SEC EDGAR, the filing index for accession 0001213900-19-003911. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.